Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question

Epilepsy and Behavior

Volumn 38, Issue , 2014, Pages 3-7

  Kanner, Andres M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

1 Interleukin; Gamma aminobutyric acid; Glutamate; Hippocampal atrophy; Hypothalamic pituitary adrenal hyperactivity; Major depressive disorder; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLUTAMIC ACID; INTERLEUKIN 1BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

CLINICAL OBSERVATION; COMPLEX PARTIAL SEIZURE; CORTICAL DYSPLASIA; DEPRESSION; ENDOCRINE DISEASE; EPILEPSY; FRONTAL CORTEX; HIPPOCAMPAL SCLEROSIS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MATERNAL DEPRIVATION; ORBITAL CORTEX; PREFRONTAL CORTEX; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT EPILEPSY; TUBEROUS SCLEROSIS; ANIMAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DEPRESSIVE DISORDER; EPILEPSY; HUMANS;

EID: 84910650849     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.06.027     Document Type: Review

References (93)

1. Tellez-Zenteno J.F., Patten S.B., Jetté N., Williams J., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344.
2. Boylan L.S., Flint L.A., Labovitz D.L., Jackson S.C., Starner K., Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 2004, 62:258-261.
3. Cramer J.A., Blum M., Reed M., Fanning K., Epilepsy Impact Project The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003, 4:515-521.
4. Johnson E.K., Jones J.E., Seidenberg M., Hermann B.P. The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy. Epilepsia 2004, 45:544-550.
5. Perrine K., Hermann B.P., Meador K.J., Vickrey B.G., Cramer J.A., Hays R.D., et al. The relationship of neuropsychological functioning to quality of life in epilepsy. Arch Neurol 1995, 52:997-1003.
6. Kanner A.M., Barry J.J., Gilliam F., Hermann B., Meador K.J. Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy?. Epilepsia 2010, 51(7):1152-1158.
7. Kanner A.M., Barry J.J., Gilliam F., Hermann B., Meador K.J. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events?. Epilepsia 2012, 53(6):1104-1108.
8. Perucca P., Jacoby A., Marson A.G., Baker G.A., Lane S., Benn E.K., et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 2011, 8(76(3)):273-279.
9. Hitiris N., Mohanraj R., Norrie J., et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75:192-196.
10. Petrovski S., Szoeke C.E.I., Jones N.C., Salzberg M.R., Sheffield L.J., Huggins R.M., et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010, 75:1015-1021.
11. Kanner A.M., Byrne R., Chicharro A., et al. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009, 72:793-799.
12. Cleary R.A., Thompson P.J., Fox Z., Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery. Epilepsia 2012, 53(10):1705-1712.
13. de Araújo Filho G.M., Gomes F.L., Mazetto L., Marinho M.M., Tavares I.M., Caboclo L.O., et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure 2012, 8:619-623.
14. Alper K.R., Schwartz K.A., Kolts R.L., Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007, 62:345-354.
15. Forsgren L., Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res 1990, 6:66-81.
16. Hesdorffer D.C., Hauser W.A., Annegers J.F., Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000, 47:246-249.
17. Hesdorffer D.C., Hauser W.A., Ludvigsson P., Olafsson E., Kjartansson O. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol 2006, 59:35-41.
18. Hesdorffer D.C., Ishihara L., Mynepalli L., Webb D.J., Weil J., Hauser W.A. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012, 72:184-191.
19. Adelow C., Anderson T., Ahlbom A., Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012, 78:396-401.
20. Evans D.L., Charney D. Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003, 54:177-180.
21. Zobel A., Wellmer J., Schulze-Rauschenbach S., Pfeiffer U., Schnell S., Elger C., et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci 2004, 254:303-311.
22. Salzberg M., Kumar G., Supit L., Jones N.C., Morris M.J., Rees S., et al. Early postnatal stress confers enduring vulnerability to limbic epileptogenesis. Epilepsia 2007, 48:2079-2085.
23. Jones N.C., Kumar G., O'Brien T.J., Morris M.J., Rees S.M., Salzberg M.R. Anxiolytic effects of rapid amygdala kindling, and the influence of early life experience in rats. Behav Brain Res 2009, 12(203):81-87.
24. Karst H., de Kloet E.R., Joëls M. Episodic corticosterone treatment accelerates kindling epileptogenesis and triggers long-term changes in hippocampal CA1 cells, in the fully kindled state. Eur J Neurosci 1999, 11:889-898.
25. Taher T.R., Salzberg M., Morris M.J., Rees S., O'Brien T.J. Chronic low-dose corticosterone supplementation enhances acquired epileptogenesis in the rat amygdala kindling model of TLE. Neuropsychopharmacology 2005, 30:1610-1616.
26. Kumar G., Couper A., O'Brien T.J., Salzberg M.R., Jones N.C., Rees S.M., et al. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 2007, 32:834-842.
27. Kumar G., Jones N.C., Morris M.J., Rees S., O'Brien T.J., Salzberg M.R. Early life stress enhancement of limbic epileptogenesis in adult rats: mechanistic insights. PLoS One 2011, 6:e24033.
28. Castro O.W., Santos V.R., Pun R.Y., McKlveen J.M., Batie M., Holland K.D., et al. Impact of corticosterone treatment on spontaneous seizure frequency and epileptiform activity in mice with chronic epilepsy. PLoS One 2012, 7(9):e46044. 10.1371/journal.pone.0046044.
29. Kanner A.M. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?. Lancet Neurol 2012, 11(12):1093-1102.
30. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
31. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 15(22):3251-3261.
32. Hattiangady B., Shetty A.K. Implications of decreased hippocampal neurogenesis in chronic temporal lobe epilepsy. Epilepsia 2008, 49(Suppl. 5):26-41.
33. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
34. Sheline Y., Wang P.W., Gado M.H. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996, 93:3908-3913.
35. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115-118.
36. Öngür D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998, 95:13290-13295.
37. Rajkowska G., Miguel-Hidalgo J.J., Wei J. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
38. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001, 55:585-595.
39. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553.
40. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002, 12:386-394.
41. Salgado P.C., Yasuda C.L., Cendes F. Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy Behav 2010, 19:422-427.
42. Bilevicius E., Yasuda C.L., Silva M.S., Guerreiro C.A., Lopes-Cendes I., Cendes F. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology 2010, 9(75):1695-1701.
43. Umeoka E.H., Garcia S.B., Antunes-Rodrigues J., Elias L.L., Garcia-Cairasco N. Functional characterization of the hypothalamic-pituitary-adrenal axis of the Wistar Audiogenic Rat (WAR) strain. Brain Res 2011, 1381:141-147. 10.1016/j.brainres.2011.01.042.
44. Prendiville S., Gale K. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 1993, 34(2):381-384.
45. Mazarati A.M., Siddarth P., Baldwin R.A., Sankar R. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
46. Clinckers R., Smolders I., Meurs A., et al. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D2 and 5-HT1A receptors. J Neurochem 2004, 89:834-843.
47. Dailey J.W., Mishra P.K., Ko K.H., Penny J.E., Jobe P.C. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life Sci 1992, 50:319-326.
48. Lopez-Meraz M.L., Gonzalez-Trujano M.E., Neri-Bazan L., Hong E., Rocha L.L. 5-HT1A receptor agonists modify seizures in three experimental models in rats. Neuropharmacology 2005, 49:367-375.
49. Meldrum B.S., Anlezark G.M., Adam H.K., et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology (Berl) 1982, 76:212-217.
50. Piette Y., Delaunois A.L., De Shaepdryver A.F., et al. Imipramine and electroshock threshold. Arch Int Pharmacodyn Ther 1963, 144:293-297.
51. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 15(35):1558-1568.
52. Brennan T.J., Seeley W.W., Kilgard M., Schreiner C.E., Tecott L.H. Sound-induced seizures in serotonin 5-HT2c receptor mutant mice. Nat Genet 1997, 16(4):387-390.
53. Yan Q.S., Jobe P.C., Dailey J.W. Further evidence of anticonvulsant role for 5-hydroxytryptamine in genetically epilepsy prone rats. Br J Pharmacol 1995, 115:1314-1318.
54. Yan Q.S., Jobe P.C., Dailey J.W. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 1993, 252(1):105-112.
55. Hamida H and Kanner AM.
56. Toczek M.T., Carson R.E., Lang L. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003, 60:749-756.
57. Hasler G., Bonwetsch R., Giovacchini G. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007, 62:1258-1264.
58. Savic I., Lindstrom P., Gulyas B., Halldin C., Andree B., Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004, 62:1343-1351.
59. Sargent P.A., Kjaer K.H., Bench C.J., et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000, 57:174-180.
60. Levine K., Panchalingam K., Rapaport S., Gershon S., McClure R.J., Pettegrew J.W. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000, 47:586-593.
61. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005, 10:808-819.
62. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155-1158.
63. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains of patients with mood disorders. Biol Psychiatry 2007, 25:1310-1316.
64. Sanacora G., Mason G.F., Rothman D.L., Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002, 159:663-665.
65. Zink M., Vollmayr B., Gebicke-Haerter P.J., Henn F.A. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2010, 58:465-473.
66. McCullumsmith R.E., Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002, 26:368-375.
67. Zarate C.A., Quiroz J., Payne J., Manji H.K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002, 36:35-83.
68. Machado-Vieira R., Salvadore G., Ibrahim L.A., Diaz-Granados N., Zarate C.A. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009, 15:1595-1611.
69. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
70. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864.
71. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
72. Bonanno G., Giambelli R., Raiteri L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005, 25:3270-3279.
73. Gerner R.H., Hare T.A. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 1981, 138:1098-1101.
74. Sanacora G., Mason G.F., Rothman, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999, 56:1043-1047.
75. Sanacora G., Gueorguieva R., Epperson, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
76. Bhagwagar Z., Wylezinska M., Jezzard, et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007, 61:806-812.
77. Sanacora G., Mason G.F., Rothman D.L., Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002, 159:663-665.
78. Sanacora G., Mason G.F., Rothman D.L., et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003, 160:577-579.
79. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64:193-200.
80. Price R.B., Shungu D.C., Mao X., Nestadt P., Kelly C., Collins K.A., et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 2009, 65:792-800.
81. Rajkowska G., O'Dwyer G., Teleki Z., Stockmeier C.A., Miguel-Hidalgo J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007, 32:471-482.
82. Kujirai T., Caramia M.D., Rothwell J.C., et al. Corticocortical inhibition in human motor cortex. J Physiol 1993, 471:501-519.
83. Davies C.H., Davies S.N., Collingridge G.L. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. J Physiol 1990, 424:513-531.
84. Bajbouj M., Lisanby S.H., Lang U.E., Danker-Hopfe H., Heuser I., Neu P. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry 2006, 59:395-400.
85. Levinson A.J., Fitzgerald P.B., Favallli G., Blumberger D.M., Daigle M., Daskalakis Z.J. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 2010, 67:458-464.
86. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25-45.
87. Vezzani A., Conti M., De Luigi A., et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999, 19:5054-5065.
88. Vezzani A., Moneta D., Conti M., et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci U S A 2000, 97:11534-11539.
89. Vezzani A., Balosso S., Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008, 22:797-803.
90. Crespel A., Coubes P., Rousset M.C., et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res 2002, 952:159-169.
91. Ravizza T., Boer K., Redeker S., et al. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 2006, 24:128-143.
92. Boer K., Jansen F., Nellist M., et al. Inflammatory processes in cortical tubers, and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res 2008, 78:7-21.
93. Hu S., Sheng W.S., Ehrlich L.C., Peterson P.K., Chao C.C. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000, 7:153-159.